Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
NCT05400109
Recruiting
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Non Hodgkin Lymphoma
Register for Updates
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05286788
Recruiting
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
06/06/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Register for Updates
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
NCT05278208
Recruiting
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
06/06/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Register for Updates
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986
Recruiting
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/06/2025
Locations: Travere Investigational Site, Columbus, Ohio
Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, Alport Syndrome, IgA Vasculitis
Register for Updates
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
NCT04069312
Recruiting
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/06/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)
NCT06499285
Recruiting
This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk MDS, or more recently defined as myelodysplastic neoplasms, with or without ring sideroblasts. The study is divided into the Screening Period, Double-blind Treatment Period, Safety Follow-Up Period and Long-term Follow-up Period. Approximately 255 participants will be enrolled, randomized 2:1 to re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Study Site 1100, Canton, Ohio
Conditions: Myelodysplastic Syndromes
Register for Updates
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/05/2025
Locations: MidWest Eye Center, Cincinnati, Ohio
Conditions: Age Related Macular Degeneration (ARMD)
Register for Updates
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485
Recruiting
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Miami Valley Hospital South, Centerville, Ohio
Conditions: Rectal Cancer
Register for Updates
Development of MRF for Characterization of Brain Tumors After Radiotherapy
NCT06101069
Recruiting
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participan... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
06/05/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
Register for Updates
Nourishing Beginnings: Addressing Food Insecurity During Pregnancy
NCT05341960
Recruiting
This is a pilot project designed to test the feasibility of implementing a community health worker (CHW)-led intervention to improve nutritious food access and consumption among pregnant people and to evaluate the effectiveness of this approach. The project will be conducted in partnership with the Greater Cleveland Food Bank and the Better Health Partnership Community Health Worker HUB
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Mom's First, Cleveland, Ohio
Conditions: Pregnancy Related, Food Insecurity, Premature Birth, Pregnancy Complications
Register for Updates
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/05/2025
Locations: The Cleveland Clinical Foundation, Cleveland, Ohio
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates